Livzon Pharmaceutical repurchases A-shares while H-share count remains unchanged

Livzon Pharmaceutical Group reported no changes in its H-share capital, with 299,807,117 H-shares remaining outstanding as of September 2, 2025. This figure is consistent with the H-share count at the beginning of the reporting period on September 1, 2025. The company's H-shares are listed on the Hong Kong Stock Exchange.

In contrast, the company engaged in a series of A-share repurchases, totaling 71,400 A-shares on September 2, 2025. These repurchases were conducted on the Shenzhen Stock Exchange at prices ranging from RMB 41.24 to RMB 41.99 per share, with a total consideration of RMB 2,977,770. The A-shares are listed on the Shenzhen Stock Exchange.

The cumulative A-shares repurchased by September 2, 2025, amounted to 71,400, all of which are intended for cancellation but are not yet cancelled. The company confirmed that all disclosed share repurchases comply with relevant listing rules and regulatory requirements.